Targeting pancreatic cancer stem cells for cancer therapy

Biochim Biophys Acta. 2012 Dec;1826(2):385-99. doi: 10.1016/j.bbcan.2012.06.002. Epub 2012 Jun 20.

Abstract

Pancreatic cancer (PC) is the fourth most frequent cause of cancer death in the United States. Emerging evidence suggests that pancreatic cancer stem cells (CSCs) play a crucial role in the development and progression of PC. Recently, there is increasing evidence showing that chemopreventive agents commonly known as nutraceuticals could target and eliminate CSCs that have been proposed as the root of the tumor progression, which could be partly due to attenuating cell signaling pathways involved in CSCs. Therefore, targeting pancreatic CSCs by nutraceuticals for the prevention of tumor progression and treatment of PC may lead to the development of novel strategy for achieving better treatment outcome of PC patients. In this review article, we will summarize the most recent advances in the pancreatic CSC field, with particular emphasis on nutraceuticals that target CSCs, for fighting this deadly disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Drug Resistance, Neoplasm
  • Hedgehog Proteins / antagonists & inhibitors
  • Humans
  • Neoplasm Metastasis
  • Neoplastic Stem Cells / drug effects*
  • Neoplastic Stem Cells / physiology
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / pathology
  • Receptors, CXCR4 / antagonists & inhibitors
  • Receptors, Notch / antagonists & inhibitors
  • Signal Transduction / drug effects
  • TOR Serine-Threonine Kinases / antagonists & inhibitors

Substances

  • Hedgehog Proteins
  • Receptors, CXCR4
  • Receptors, Notch
  • TOR Serine-Threonine Kinases